Overview

Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the dosing strategy for adolescents aged 2 to 5 years.
Phase:
Phase 1
Details
Lead Sponsor:
Kyowa Kirin Pharmaceutical Development Ltd
Prostrakan Pharmaceuticals
Treatments:
Granisetron